Advancing CART therapy for acute myeloid leukemia : recent breakthroughs and strategies for future development
Pérez-Amill, Lorena (Department of Immunology. Centre de Diagnòstic Biomèdic (CDB). Hospital Clínic de Barcelona)
Bataller, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Delgado, Julio (Universitat de Barcelona)
Esteve, Jordi (Universitat de Barcelona)
Juan, Manel (Hospital Sant Joan de Déu (Barcelona, Catalunya))
Klein-González, Nelia (Hospital Clínic i Provincial de Barcelona)

Data:	2023
Resum:	Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid leukemia (AML) on the basis of the results obtained for other haematological malignancies and the need of new treatments for relapsed and refractory AML. The biggest challenge of CART therapy for AML is to identify a specific target antigen, since antigens expressed in AML cells are usually shared with healthy haematopoietic stem cells (HSC). The concomitant expression of the target antigen on both tumour and HSC may lead to on-target/off-tumour toxicity. In this review, we guide researchers to design, develop, and translate to the clinic CART therapies for the treatment of AML. Specifically, we describe what issues have to be considered to design these therapies; what in vitro and in vivo assays can be used to prove their efficacy and safety; and what expertise and facilities are needed to treat and manage patients at the hospital.
Ajuts:	Ministerio de Ciencia e Innovación 10.13039/501100011033
Nota:	The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Supported by Secretaria d'Universitat i Recerca del Departament d'Empresa i Coneixement, Generalitat de Catalunya, project 2020PANDE00079. LP-A is funded by "Programa Torres Quevedo" grant PTQ2020-011012 funded by MCIN/AEI/10.13039/501100011033; Gyala Therapeutics and FCRB-IDIBAPS are funded by project CPP2021-008553 funded by MCIN/AEI/10. 13039/501100011033 and by the European Union 'NextGenerationEU/PRTR; Gyala Therapeutics is funded by a project from CDTI with the collaboration of the Ministry of Science and Innovation and co-financed by the European Union Next Generation EU with the file number SNEO-2021111060 (subsidized by CDTI). The project that gave rise to these results has received funding from "la Caixa" Foundation*under the grant agreement LCF/PR/SP23/52950004.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Matèria:	Acute myeloid leukemia ; Chimeric antigen receptor ; Myelotoxicity ; Hematologic toxicity ; Cytopenia ; On-target/off-tumor toxicity
Publicat a:	Frontiers in immunology, Vol. 14 (2023) , p. 1260470, ISSN 1664-3224

DOI: 10.3389/fimmu.2023.1260470
PMID: 38098489

22 p, 2.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats
Articles > Ressenyes